Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Net Cash Flow (2020 - 2025)

Insight Molecular Diagnostics' Net Cash Flow history spans 6 years, with the latest figure at -$5.7 million for Q3 2025.

  • For Q3 2025, Net Cash Flow rose 3.41% year-over-year to -$5.7 million; the TTM value through Sep 2025 reached $15.2 million, up 246.47%, while the annual FY2024 figure was -$796000.0, 93.41% up from the prior year.
  • Net Cash Flow for Q3 2025 was -$5.7 million at Insight Molecular Diagnostics, up from -$6.7 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $51.8 million in Q1 2021 and bottomed at -$15.2 million in Q1 2022.
  • The 5-year median for Net Cash Flow is -$4.4 million (2023), against an average of $603789.5.
  • The largest YoY upside for Net Cash Flow was 1041.85% in 2021 against a maximum downside of 5764.38% in 2021.
  • A 5-year view of Net Cash Flow shows it stood at -$7.7 million in 2021, then crashed by 36.39% to -$10.5 million in 2022, then skyrocketed by 58.76% to -$4.4 million in 2023, then surged by 220.71% to $5.3 million in 2024, then crashed by 208.0% to -$5.7 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Net Cash Flow are -$5.7 million (Q3 2025), -$6.7 million (Q2 2025), and $22.4 million (Q1 2025).